In Conversation: Dave Hickey, EVP and President of Life Sciences, BD

Published on :

BioBuzz recently chatted with Dave Hickey, Executive Vice President and President of the BD Life Science segment, to learn more about he landed at BD, how he grew with the company, and how he led the BD Integrated Diagnostic Solutions (IDS) team to success during the early days of the COVID-19 pandemic.

In Conversation: Marcia Fournier, PhD, Founder and President of Dimensions Sciences

Published on :

The United States offers a plethora of opportunities to grow and establish yourself as a scientist, but the roads to get there aren’t equal for everybody. Marginalized groups face a particular set of challenges, especially if someone is from another country. Language can be a barrier. Finding funding can be a challenge. Student visas have strict requirements. It’s hard to find friends or mentors to help you. The list goes on.

In Conversation: Nao Gamo, PhD, Founder and CEO of NeuroSonics Medical, Vice President of BD at MDC Studio, Associate at Verte Family of Funds, and Executive Women In Bio Chapter Vice Chair

Published on :

Dr. Nao Gamo has led NeuroSonics Medical since its incorporation. Before becoming an entrepreneur, she spent 15 years as an academic researcher in neuroscience and psychiatry, with a focus on the molecular and cellular mechanisms underlying cognitive impairment related to psychiatric disorders. She was also an Adjunct Assistant Research Engineer and Research Associate in Biomedical Engineering at the Johns Hopkins University, where she worked to develop the NeuroSonics Medical technology. 

In Conversation With Gilda D’Incerti, Founder and CEO of PQE Group

Published on :

In celebration of International Women’s Day, BioBuzz caught up with D’Incerti to learn more about the story behind the company, how PQE Group has continued to grow tremendously across the wordl, and its plans for the future.

In Conversation with Gaspar Canepa, PhD, Principal Scientist at American Gene Technologies®

Published on :

You likely know AGT best from their ongoing work to develop a potential HIV cure. Their lead candidate, AGT103-T, is currently in a Phase 1 trial and has shown encouraging data thus far both in patient safety and T cell responses. The company is currently planning for Phase 2.

In Conversation with Rafiq Islam, Ph.D., Vice President, Bioanalysis and Biomarkers at Amador Bioscience and Maryland Site Head

Published on :

Amador Bioscience is a translational and early clinical development partner for companies developing new drugs. Make no mistake, though – Amador is different from many Contract Research Organizations (CROs) out there, using the latest scientific advancements as its north star to guide its decisions. The company leans on its technology-driven and AI-enabled capabilities to modernize clinical research and bioanalytical testing to accelerate new drugs through the development pipeline.

In Conversation with Anne Le, M.D, H.D.R., Founder and CEO of Gigantest

Published on :

Serving as a professor at Johns Hopkins for over a decade, Dr. Le recently decided to step out of her comfort zone and start her own company in Baltimore’s Inner Harbor, Gigantest, which provides next-level metabolomics services for scientists and physicians at leading institutions around the world.

In Conversation: Barry Wells, MD, Director of Business Development, American Gene TechnologiesⓇ

Barry Wells
Published on :

Rockville, Maryland’s American Gene Technologies (AGT™) HIV cure program has been making remarkable progress in its mission to bring a single-dose cure to people living with HIV. That mission is steadily advancing through a successful Phase 1 human clinical trial. The company hopes to begin its Phase 2 study during 2023; this could yield very compelling data towards a functional cure, occurring perhaps as early as the first half of 2024.